Open Access

Table 8

Detailed description of thromboembolic events.

Age (days) Procedure Site of thrombus Time of thrombus (days after procedure) Line associated Factors used and dose
Control group
4 Aortic arch repair Left subclavian vein 0 No KcentraTM (20 ut/kg) + FEIBA (50 ut/kg) + rFVIIa (90 ug/kg)
6 Arterial switch IVC 8 UVC KcentraTM (30 ut/kg) + rFVIIa (90 ug/kg)
165 Comprehensive stage II Venous brain infarct, stroke, seizures 2 No FEIBA (100 ut/kg) + rFVIIa (180 ug/kg)
98 Truncus arteriosus repair Right common femoral vein 60 S/P previous cardiac catheterization access FEIBA (50 ut/kg) + rFVIIa (90 ug/kg)
10 MAPCAs unifocalization Left common femoral vein 10 PICC line FEIBA (50 ut/kg) + rFVIIa (90 ug/kg)
ROTEM group
5 Arterial switch IVC (near RA junction) 8 PICC line KcentraTM + rFVIIa (45 ug/kg)
8 Arterial switch Right superior femoral artery and vein 20 Cardiac Cath access KcentraTM + rFVIIa (45 ug/kg)
141 Comprehensive stage II LPA thrombus 8 No KcentraTM + rFVIIa (45 ug/kg)
150 Comprehensive stage II LPA thrombus 11 No KcentraTM + rFVIIa (45 ug/kg)
1 TAPVC Right common femoral and external iliac vein 18 Cardiac Cath access KcentraTM + rFVIIa (45 ug/kg)

MAPCA’s: Major aortopulmonary collateral arteries; TAPVC: total anomalous pulmonary venous connection; rFVIIa: activated recombinant factor VII; FEIBA: factor eight inhibitor bypass activity; KcentraTM: prothrombin complex concentrate (human); LPA: left pulmonary artery; IVC: inferior vena cava.

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.